Bolt Biotherapeutics’ (BOLT) Buy Rating Reaffirmed at HC Wainwright

Bolt Biotherapeutics (NASDAQ:BOLT)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 32.58% from the stock’s previous close.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Monday, April 20th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Bolt Biotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $41.00.

Bolt Biotherapeutics Stock Up 2.9%

BOLT stock opened at $5.28 on Thursday. Bolt Biotherapeutics has a twelve month low of $3.91 and a twelve month high of $7.35. The company has a market cap of $10.14 million, a price-to-earnings ratio of -0.32 and a beta of 1.10. The business has a 50 day moving average price of $4.71 and a two-hundred day moving average price of $5.08. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.98.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $1.50 million. Analysts anticipate that Bolt Biotherapeutics will post -9.54 EPS for the current fiscal year.

Institutional Trading of Bolt Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its holdings in Bolt Biotherapeutics by 40.3% during the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after purchasing an additional 22,200 shares during the last quarter. T3 Companies LLC bought a new position in Bolt Biotherapeutics during the 4th quarter worth $208,000. Nano Cap New Millennium Growth Fund L P bought a new position in Bolt Biotherapeutics during the 4th quarter worth $112,000. Susquehanna International Group LLP bought a new position in Bolt Biotherapeutics during the 3rd quarter worth $89,000. Finally, Shay Capital LLC bought a new position in Bolt Biotherapeutics during the 3rd quarter worth $85,000. 86.70% of the stock is owned by institutional investors and hedge funds.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.